Literature DB >> 21854372

Validation of the rat model of cryptogenic infantile spasms.

Tamar Chachua1, Mi-Sun Yum, Jana Velíšková, Libor Velíšek.   

Abstract

PURPOSE: To determine whether a new model of cryptogenic infantile spasms consisting of prenatal priming with betamethasone and postnatal trigger of spasms by N-methyl-D-aspartate (NMDA) responds to chronic adrenocorticotropic hormone (ACTH) treatment, and has electroencephalography (EEG) signature, efficacy of treatments, and behavioral impairments similar to those in human infantile spasms.
METHODS: Rats prenatally primed with betamethasone on gestational day 15 were used. Spasms were triggered with NMDA between postnatal days (P) 10 and 15 in a single session or in multiple sessions in one subject. The expression of spasms was compared to prenatally saline-injected controls. Effects of relevant treatments (ACTH, vigabatrin, methylprednisolone, rapamycin) were determined in betamethasone-primed rats. In the rats after spasms, behavioral evaluation was performed in the open field and elevated plus maze on P20-22. KEY
FINDINGS: NMDA at P10-15 (the rat "infant" period) triggers the spasms significantly earlier and in greater numbers in the prenatal betamethasone-exposed brain compared to controls. Similar to human condition, the spasms occur in clusters. Repeated trigger of spasms is associated with ictal EEG electrodecrements and interictal large-amplitude waves, a possible rat variant of hypsarrhythmia. Chronic ACTH treatment in a randomized experiment, and chronic pretreatment with methylprednisolone significantly suppress the number of spasms similar to the human condition. Pretreatment with vigabatrin, but not rapamycin, suppressed the spasms. Significant behavioral changes occurred following multiple bouts of spasms. SIGNIFICANCE: The model of infantile spasms has remarkable similarities with the human condition in semiology, EEG, pharmacologic response, and long-term outcome. Therefore, the model can be used to search for novel and more effective treatments for infantile spasms. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21854372      PMCID: PMC3169722          DOI: 10.1111/j.1528-1167.2011.03220.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  37 in total

1.  The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial.

Authors:  Andrew L Lux; Stuart W Edwards; Eleanor Hancock; Anthony L Johnson; Colin R Kennedy; Richard W Newton; Finbar J K O'Callaghan; Christopher M Verity; John P Osborne
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

Review 2.  Mechanisms of epileptogenesis and potential treatment targets.

Authors:  Asla Pitkänen; Katarzyna Lukasiuk
Journal:  Lancet Neurol       Date:  2011-02       Impact factor: 44.182

3.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

Authors:  Dos D Sarbassov; Siraj M Ali; Shomit Sengupta; Joon-Ho Sheen; Peggy P Hsu; Alex F Bagley; Andrew L Markhard; David M Sabatini
Journal:  Mol Cell       Date:  2006-04-06       Impact factor: 17.970

4.  Vigabatrin for the treatment of infantile spasms: final report of a randomized trial.

Authors:  Roy D Elterman; W Donald Shields; Richard M Bittman; Sarah A Torri; Stephen M Sagar; Stephen D Collins
Journal:  J Child Neurol       Date:  2010-04-19       Impact factor: 1.987

5.  Age-specific N-methyl-D-aspartate-induced seizures: perspectives for the West syndrome model.

Authors:  R Kábová; S Liptáková; R Slamberová; M Pometlová; L Velísek
Journal:  Epilepsia       Date:  1999-10       Impact factor: 5.864

6.  Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat.

Authors:  S Pellow; P Chopin; S E File; M Briley
Journal:  J Neurosci Methods       Date:  1985-08       Impact factor: 2.390

Review 7.  Infantile spasms.

Authors:  Mary L Zupanc
Journal:  Expert Opin Pharmacother       Date:  2003-11       Impact factor: 3.889

Review 8.  Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.

Authors:  M T Mackay; S K Weiss; T Adams-Webber; S Ashwal; D Stephens; K Ballaban-Gill; T Z Baram; M Duchowny; D Hirtz; J M Pellock; W D Shields; S Shinnar; E Wyllie; O C Snead
Journal:  Neurology       Date:  2004-05-25       Impact factor: 9.910

9.  High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study.

Authors:  T Z Baram; W G Mitchell; A Tournay; O C Snead; R A Hanson; E J Horton
Journal:  Pediatrics       Date:  1996-03       Impact factor: 7.124

10.  Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat.

Authors:  S Pellow; S E File
Journal:  Pharmacol Biochem Behav       Date:  1986-03       Impact factor: 3.533

View more
  31 in total

1.  Knockin' Out the Spasms.

Authors:  Libor Velíšek
Journal:  Epilepsy Curr       Date:  2017 May-Jun       Impact factor: 7.500

Review 2.  mTOR inhibition in epilepsy: rationale and clinical perspectives.

Authors:  Adam P Ostendorf; Michael Wong
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

Review 3.  Clinical Potential of Neurosteroids for CNS Disorders.

Authors:  Doodipala Samba Reddy; William A Estes
Journal:  Trends Pharmacol Sci       Date:  2016-05-05       Impact factor: 14.819

Review 4.  Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design.

Authors:  Michele Simonato; Wolfgang Löscher; Andrew J Cole; F Edward Dudek; Jerome Engel; Rafal M Kaminski; Jeffrey A Loeb; Helen Scharfman; Kevin J Staley; Libor Velíšek; Henrik Klitgaard
Journal:  Epilepsia       Date:  2012-06-18       Impact factor: 5.864

5.  Adrenocorticotropic hormone protects learning and memory function in epileptic Kcna1-null mice.

Authors:  Morris H Scantlebury; Kyoung-Chul Chun; Shun-Chieh Ma; Jong M Rho; Do Young Kim
Journal:  Neurosci Lett       Date:  2017-02-27       Impact factor: 3.046

6.  mTOR as a potential treatment target for epilepsy.

Authors:  Michael Wong
Journal:  Future Neurol       Date:  2012-09-01

7.  Preclinical safety and efficacy of cannabidivarin for early life seizures.

Authors:  Megan N Huizenga; Alberto Sepulveda-Rodriguez; Patrick A Forcelli
Journal:  Neuropharmacology       Date:  2019-01-10       Impact factor: 5.250

Review 8.  Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: A view from preclinical studies.

Authors:  Aristea S Galanopoulou; Solomon L Moshé
Journal:  Neurobiol Dis       Date:  2015-05-09       Impact factor: 5.996

Review 9.  Basic mechanisms of catastrophic epilepsy -- overview from animal models.

Authors:  Aristea S Galanopoulou
Journal:  Brain Dev       Date:  2013-01-11       Impact factor: 1.961

Review 10.  Latest American and European updates on infantile spasms.

Authors:  Andrew L Lux
Journal:  Curr Neurol Neurosci Rep       Date:  2013-03       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.